Enanta Pharmaceuticals, Inc.

NASDAQ:ENTA

Biotechnology

Healthcare
$8.23 -0.67%

-$0.09 today

Market cap
$239.70M
Beta
0.99
P/E (TTM)
-4.3
EPS (TTM)
-$2.90
52W Low $6.44High $17.15

Volume 0.81M

Average 0.17M

ENTA Accounts Payables

Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.

Enanta Pharmaceuticals, Inc.NASDAQ: ENTA

Accounts Payables · Q2 FY2026 · quarter ended Mar 2026

Accounts payables grows, but more slowly than its trailing trend

Q2 FY2026 accounts payables of $2.48M rose 183.8% year over year, behind the +1230.0% change in trailing-twelve-month accounts payables. Over 3 fiscal years it compounded at -34.4% a year.

Context

  • Accounts payables amounted to 2.0% of revenue in FY2025, up 1.4 pp from a year earlier.
  • Accounts payables grew in size in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from +183.8% toward the trailing-twelve-month pace of +1230.0%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$2.48M+4033.3% QoQ
Last fiscal yearSep 2025
-$1.31M+216.7% YoY
LTMMar 2026
$399K+1230.0% YoY
Accounts Payables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+183.8%——
1 year+216.7%——
3-year CAGR-34.4%——
5-year CAGR——
10-year CAGR——

Accounts Payables history

USD · from the cash flow

Latest · FY2025
(1.31M) USD
Year-over-year change
-216.7%

Accounts Payables vs competitors

How ENTA compares with its peers on the latest reported figures

  • ENTA's LTM Mar 2026 accounts payables of $399K is the 6th largest of the 11 companies compared; the peer median is $143.25K.
  • Its year-over-year change of +1230.0% is the highest of 11, against a peer median of +86.7%.
  • Accounts payables amounts to 0.6% of revenue for ENTA, versus a peer median of 3.3%.
ENTA Competitors Peer median
Accounts Payables for ENTA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
PRLDPrelude Therapeutics IncorporatedLTM Mar 2026$3.89M -608.8%+124.3%23.2%
TNYATenaya Therapeutics, Inc.LTM Mar 2026$2.51M +12.5%—1116.0%
PYXSPyxis Oncology, Inc.LTM Mar 2026$2.14M +288.2%—15.5%
AVIRAtea Pharmaceuticals, Inc.LTM Mar 2026$2.06M +115.0%——
FHTXFoghorn Therapeutics Inc.LTM Mar 2026$793K -49.2%-33.2%2.8%
ENTAEnanta Pharmaceuticals, Inc.LTM Mar 2026$399K +1230.0%-34.4%0.6%
CRBUCaribou Biosciences, Inc.LTM Mar 2026$370K -77.8%—3.3%
NAUTNautilus Biotechnology, Inc.LTM Mar 2026$262K +132.6%-50.3%—
ASMBAssembly Biosciences, Inc.LTM Mar 2026$254K +71.6%—0.4%
IMRXImmuneering CorporationLTM Mar 2026$197.49K +121.5%——
VYGRVoyager Therapeutics, Inc.LTM Mar 2026$89K +101.8%-20.1%0.2%
Peer median (excluding ENTA) $143.25K+86.7%-26.6%3.3%

Competitors are the stored peer set for ENTA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Sep 2021
FY2022
Sep 2022
FY2023
Sep 2023
FY2024
Sep 2024
FY2025
Sep 2025
Net Income(79M)(121.76M)(133.82M)(116.05M)(81.89M)
Depreciation & Amortization3.33M2.97M2.37M2.34M5.09M
Deferred Income Tax345K0000
Stock-Based Compensation20.99M26.97M28.22M26.8M18.57M
Change in Working Capital(13.69M)6.79M8.02M7.13M39.91M
Accounts Receivables(24.3M)11.8M9.42M973K31.76M
Inventory00000
Accounts Payables3.77M(4.63M)(1.15M)(414K)(1.31M)
Other Working Capital6.84M(372K)(243K)6.57M9.46M
Other Non-Cash Items(1.98M)242K(7.95M)1.02M(946K)
Operating Cash Flow(70M)(84.78M)(103.15M)(78.76M)(19.27M)
Capital Expenditures(750K)(2.13M)(9.06M)(17.95M)(12.9M)
Acquisitions (Net)(37.74M)(54.9M)44.52M00
Purchases of Investments(307.35M)(171.45M)(373.39M)(307.28M)(209.63M)
Sales of Investments345.09M228.47M328.87M383.47M262.87M
Other Investing Activities37.74M54.9M(44.52M)00
Investing Cash Flow36.99M54.9M(53.58M)58.24M40.35M
Debt Repayment00199.68M(27.48M)(26.49M)
Common Stock Issued3.61M21.26M2.21M147K145K
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(534K)(1.23M)(3.76M)(294K)(277K)
Financing Cash Flow3.08M20.03M198.13M(27.63M)(26.62M)
Effect of Forex Changes00000
Net Change in Cash(29.93M)(9.85M)41.39M(48.16M)(5.54M)
Free Cash Flow(70.75M)(86.91M)(112.21M)(96.71M)(32.17M)

Enanta Pharmaceuticals, Inc.

NASDAQ:ENTA

Intrinsic Alpha fair value

Locked

Current Price

$8.23

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.